NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

LF:

You may be right. However, if memory serves me correctly, I believe sometime back, LP talked about molecular sub-groupings as part of "many chances to win". Of course, she was aware of the fact that UCLA studies addressed these groupings. It may be that earlier patients were not so classified just like, for example, methylation status for 38 initial patients, but subsequent patient entries noted sub molecular categorizations that could be analyzed. There was much discussion concerning MOA and the classification of sub types into immunogenic and less immunogenic. MES was very immunogenic and thus more likely to respond to SOC and DCVAX. Soft tissue sarcoma was also so classified. OTOH, pro-neural was found to be less immunogenic but not as aggressive as MES and less/not responsive.

So it is possible that these sub grouping classifications were noted later on in the trial. Whether results from such data are SS is of course unknown. Accordingly, I tend to think that there will be sub group molecular analysis. These sub groupings became well known during the course of the trial which due to its length and breadth is a mother load of data. Hard to believe that molecular sub grouping data was not accumulated for analysis given what was known. JMHO.